Prostate cancer screening drops dramatically in middle-aged men

November 17, 2015

(Nov. 17, 2015, BOSTON) - PSA testing has dropped significantly in middle-aged men after a 2012 recommendation that all men should not be routinely screened for prostate cancer, according to a new study published in the Journal of the American Medical Association.

The study, published as a research letter online, focused on the use of PSA - prostate-specific antigen - to screen for prostate cancer.

The study, conducted jointly at the Center for Surgery and the Public Health at Brigham and Women's Hospital (BWH) in Boston and Henry Ford Health System's Vattikuti Urology Institute in Detroit, looked at PSA screening data before and after a 2012 recommendation by the US Preventive Services Task Force (USPSTF). The USPSTF recommended against PSA screening for all men, regardless of age.

"It appears middle-aged men are hearing the message," says the study's lead author, Henry Ford Health System urologist Jesse Sammon, D.O., who also serves as a fellow at BWH. "The problem is they're controversial recommendations and very high quality evidence supports the consideration of PSA screening for many men."

The researchers found the biggest declines were seen in men ages 50-54 years old, from 23% undergoing PSA screening in 2010 to 18% in 2013, and men ages 60-64, from 45% to 35%.

"Decreased screening will most likely lead to fewer prostate cancer diagnoses," says the study's senior author, Quoc-Dien Trinh, M.D., also a urology surgeon at BWH. "Some will think that this is a good thing, as fewer men will be subjected to the harms of overtreatment, while others may be concerned with its potentially catastrophic consequences, with more men presenting with advanced, metastatic prostate cancer. The study findings also suggest that policy statements can have a significant impact on how providers deliver preventive care."

The study also found that men 75 years and older are still not following a 2008 recommendation against screening for older men, with the percentage undergoing screening remaining largely unchanged over the study period.

"Our findings suggest that younger men may be forgoing screening at a higher rate than older men following the 2012 USPSTF recommendations, and this is the population that may benefit most from screening," says Dr. Sammon.

Though credited with a significant improvement in 5-year cancer survival rates during the first decade after the FDA approved PSA testing of men without symptoms, its use for routine screening is controversial.

The test can produce false-positives, leading to unnecessary treatment and the possibility of side effects such as impotence and urinary incontinence.

But many professional organizations, including the American Urologic Association and the American Cancer Society, continue to advocate for various levels of PSA screening, depending on age.

"While the US Preventive Services Task Force does not support the use of screening, other organizations support a more balanced, joint decision-making process between patients and their healthcare providers, particularly in those men ages 55 to 75," says Dr. Sammon.

The researchers examined PSA screening data for 20,757 men from the 2000, 2005, 2010 and 2013 National Health Interview Survey (NHIS), which had an 80% survey response rate.

The findings suggest that the USPSTF's 2012 recommendations could have affected decision making for younger men and/or their doctors. According to the researchers, economic recession or a delayed response to the 2008 recommendations may have also contributed to the study findings.
EDITORS: Video quotes by and photos of Drs. Sammon and Trinh are available upon request.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits, nearly 46,000 inpatient stays and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $600 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.

Henry Ford Health System, one of the largest and most comprehensive integrated health care systems in the United States, is celebrating 100 years as a national leader in clinical care, research and education. The metro Detroit health system includes the 1,200-member Henry Ford Medical Group, five hospitals, Health Alliance Plan (a health insurance and wellness company), Henry Ford Physician Network, a 150-site ambulatory network and many other health-related entities, providing a full continuum of care throughout southeast Michigan. In 2014, Henry Ford provided $317 million in uncompensated care. The health system also is a major economic driver in Michigan and employs more than 23,000 employees. Henry Ford is a 2011 Malcolm Baldrige National Quality Award recipient. The health system is led by CEO Nancy Schlichting. To learn more, visit

Media Contacts:

Johanna Younghans
Brigham and Women's Hospital

Tammy Battaglia
Henry Ford Health System

Brigham and Women's Hospital

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to